Objective       To determine the effects of exenatide on the expression of C-peptide and on the clinical outcome in the treatment of type 2 diabetes.       Methods      A total of 78 hospitalized patients with type 2 diabetes in our department from January 2012 to June 2013 were prospectivel

y recruited

and then divided into 2 groups

the control group and the treatment group. The treatment group had 39 patients

including 16 males and 23 females

at an average age of 49.0±6.0

and received metformin combined with exenatide. Whereas

there were 39 patients in the control group

including 21 males and 18 females

with the average age of 50.1±5.9 and being given metformin combined with Gansulin. All these patients were treated for 16 weeks. The indicates

including fasting blood glucose (FBG)

2-hour postprandial blood glucose (2hPG)

glycosylated hemoglobin (HbA1c)

fasting C-peptide

2-hour postprandial C-peptide

and BMI were compared between 2 groups before and after treatment.       Results        At 16 weeks after the treatment

the fasting and 2-h postprandial C-peptide levels were increased in the treatment group (

P

0.05)

but the control group had no obvious change in the 2 indicators (

P

0.05). FBG

2hPG and HbA1c were significantly decreased in the both 2 groups (

P

0.05)

but there was no statistical difference between them (

P

0.05). The body weight

circumference of abdomen

and BMI of all the patients were decreased

and the decrease was more significantly in the treatment group than in the control group (

P

0.05).       Conclusion       Exenatide combined with metformin effectively improves the C-peptide level

and reduces blood glucose

HbA1c

body weight

circumference of abdomen and BMI in the patients with type 2 diabetes.